Edition:
India

Ono Pharmaceutical Co Ltd (4528.T)

4528.T on Tokyo Stock Exchange

2,852JPY
17 Aug 2018
Change (% chg)

¥66 (+2.37%)
Prev Close
¥2,786
Open
¥2,830
Day's High
¥2,864
Day's Low
¥2,816
Volume
2,002,700
Avg. Vol
2,179,656
52-wk High
¥3,389
52-wk Low
¥2,185

Latest Key Developments (Source: Significant Developments)

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.  Full Article

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.  Full Article

Ono Pharmaceutical completes retirement of treasury shares
Tuesday, 31 Oct 2017 

Oct 31(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31.Says the total shares outstanding 543.3 million shares after the retirement.  Full Article

BRIEF-Merus Says Ono Pharma Exercised Option For New Research And License Agreement

* MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES